Bbasic Information

CDX models play a critical role in the preclinical evaluation of anti-tumor drugs. The establishment of tumor animal models provides powerful tools for studying the mechanisms of tumor development and metastasis, as well as for screening and evaluating the efficacy of anti-tumor drugs. Currently, the available rodent tumor models include spontaneous tumor models, induced tumor models, genetically engineered mouse tumor models, as well as xenograft/allograft tumor models. Subcutaneous (s.c.) grafts, one of the transplantation models, are more widely applicable for preclinical research.
However, subcutaneous transplant tumors may not fully represent clinical cancer. The “seed and soil” theory has confirmed that the tumor’s primary organ microenvironment can influence the biological characteristics of tumor cells. Many scholars believe that subcutaneous (ectopic) transplant tumors are detached from the microenvironment of the primary tissue, and their occurrence and development are far from clinical reality. Additionally, this model exhibits poor drug responsiveness, lower metastasis rates, and survival curve data that do not correlate well with clinical outcomes. Especially in recent years, with the emergence of immune tumor therapy and the rapid growth of immunotherapy-related drugs under development, subcutaneous transplant tumor models have become increasingly inadequate to meet the demands of drug development. Therefore, a series of orthotopic transplant tumor models, which have stronger biological and pharmacological relevance to human diseases, have emerged.
Jennio has years of experience in constructing orthotopic tumor models and has established an extensive cell bank. The bank contains over 1000 different tumor cell lines from various tumor types, all of which have been identified through STR profiling, which provides valuable support for oncology research.

Services We Provide

①Stable animal models (including but not limited to)
In situ model of Lung cancer
In situ model of hepatocellular carcinoma
In situ model of breast cancer
In situ model of pancreatic cancer
In situ model of colorectal cancer
②Professional detection system (including but not limited to)
Histopathological examination
Immumohistochemical staining
Immunofluorescent staining
STR identification
Evaluation of drug efficacy
Cytokine/chemokine detection
Flow cytometry analysis
MTT/CCK8 assay
Small animal live imaging technology

Procedure of Services

Features

①Jennio possesses an extensive cell bank with over 1000 tumor cell lines that have been identified through STR profiling. The cells are stable in terms of their?status?and origin can be traced.

②Jennio has years of experience in constructing In situ tumor models and can provide customers with stable animal models for?in vivo?drug efficacy research.

③Jennio has professional research teams with members having years of GLP preclinical trial experiences, and provides high levels of drug efficacy research based on the standardized professional operations and strict quality control management systems.

④Jennio has awell-equipped testing platforms?that can meet various clinical indicator testing requirements.

⑤Jennio has experienced preclinical research experts who have collaborated with well-known domestic pharmaceutical companies to complete preclinical efficacy testing and drug clinical trial application, providing customers with strong support for drug research and development.

Representative Case

Our Laboratory

View More